Negative Reports Given by Sahm Adrangi; an Expert in Stock Market

The stock market is attracting many young and old investors. It is a good investment that comes with huge returns. The vast profits are only got by investors who do research and understand various trends in the stock market. You can also use some tips from experienced investors in the sector such as Sahm Adrangi to make the best decision on investments. He is an expert and the chief investment officer at Kerrisdale Capital Management, which is a leading investment firm that specializes in long-term investments.

 

Apart from being the chief investment officer at Kerrisdale, Sahm Adrangi is an expert when it comes to stock markets. He works hard with his team to provide reports on various companies listed in the stock market. He aims to help stock market investors with the reports he shares through the firm’s website and other third-party sites.

Recently, Sahm Adrangi has given a negative report on one internet marketing company; QuinStreet, Inc. The shares prices of this company have significantly gone up, and Sahm believes that they will go down soon. QuinStreet is a low-quality firm which is generating revenue from one client. Also, Sahm doubts the sustainability and business model of the company, which is why he is sure that its shares value will go down soon. Another firm that Kerrisdale have talked about is Eastman Kodak Company. Sahm is confident that KODAKCoin and KODAKOne will not provide material benefit to the company’s’ shareholders. Also, the revenue of the company is declining and announcing partnerships will not solve the company’s negative cash flow. The share price will go down soon and investors should be careful.

 

As for drug manufacturing companies, Sahm Adrangi has singled out Proteostasis Therapeutics. The company is the manufacturer of PTI-428; a drug that targets to manage cystic fibrosis. When the drug was granted the breakthrough by FDA, its shares prices rose. According to Sahm Adrangi, the prices will go down when the drug fails the phase 3 trials as it showed bad outcomes in Phase 2 trials.

https://seekingalpha.com/article/4052332-conversation-former-hedge-fund-analyst-long-shares-gnc